Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Accumulated Expenses (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Accumulated Expenses for 4 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 176.79% to $17.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.0 million through Dec 2025, up 176.79% year-over-year, with the annual reading at $17.0 million for FY2025, 176.79% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $17.0 million at LENZ Therapeutics, up from $12.0 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $17.0 million in Q4 2025, with the low at $500000.0 in Q1 2022.
  • Average Accumulated Expenses over 4 years is $5.4 million, with a median of $4.2 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses soared 794.75% in 2024, then tumbled 58.25% in 2025.
  • Over 4 years, Accumulated Expenses stood at $1.9 million in 2022, then grew by 1.5% to $1.9 million in 2023, then surged by 223.8% to $6.1 million in 2024, then soared by 176.79% to $17.0 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $17.0 million, $12.0 million, and $7.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.